Start Date
August 31, 2013
Primary Completion Date
September 30, 2015
Study Completion Date
November 30, 2015
TAK-733 and alisertib
"TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.~Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle."
South Texas Accelerated Research Therapeutics (START), San Antonio
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY